Drug Discovery Platform Verseon Launches Blockchain-Based Securities Exchange
U.S. pharmaceutical company Verseon has become the latest medical organization to experiment in blockchain technology, it confirmed in a press release Tuesday, September 18.
Verseon’s main product is its proprietary physics-based drug discovery platform.
The company was established in 2002 and it now trades on the London Stock Exchange, boasting a market cap of £211 million ($277 million).
“By democratizing investment access with blockchain technology, we will change the way new medicines and other life-science innovations are funded and how the resulting proceeds are shared,” Verseon CEO Adityo Prakash commented.
The move marks a continuation of the innovation which is ongoing in the wider health industry this year.
No comments: